- Home
- SJT vs LXEO Comparison
SJT vs LXEO Comparison
Compare SJT & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SJT
- LXEO
- Stock Information
- Founded
- SJT 1980
- LXEO 2017
- Country
- SJT United States
- LXEO United States
- Employees
- SJT N/A
- LXEO N/A
- Industry
- SJT Oil & Gas Production
- LXEO
- Sector
- SJT Energy
- LXEO
- Exchange
- SJT Nasdaq
- LXEO Nasdaq
- Market Cap
- SJT 212.1M
- LXEO 252.4M
- IPO Year
- SJT N/A
- LXEO 2023
- Fundamental
- Price
- SJT $4.33
- LXEO $4.88
- Analyst Decision
- SJT
- LXEO Strong Buy
- Analyst Count
- SJT 0
- LXEO 5
- Target Price
- SJT N/A
- LXEO $23.80
- AVG Volume (30 Days)
- SJT 311.6K
- LXEO 210.0K
- Earning Date
- SJT 11-14-2024
- LXEO 01-28-2025
- Dividend Yield
- SJT 2.56%
- LXEO N/A
- EPS Growth
- SJT N/A
- LXEO N/A
- EPS
- SJT 0.19
- LXEO N/A
- Revenue
- SJT $11,031,594.00
- LXEO N/A
- Revenue This Year
- SJT N/A
- LXEO N/A
- Revenue Next Year
- SJT N/A
- LXEO N/A
- P/E Ratio
- SJT $23.54
- LXEO N/A
- Revenue Growth
- SJT N/A
- LXEO N/A
- 52 Week Low
- SJT $3.21
- LXEO $4.78
- 52 Week High
- SJT $5.81
- LXEO $19.50
- Technical
- Relative Strength Index (RSI)
- SJT 54.82
- LXEO 29.67
- Support Level
- SJT $4.36
- LXEO $4.78
- Resistance Level
- SJT $4.81
- LXEO $7.66
- Average True Range (ATR)
- SJT 0.23
- LXEO 0.56
- MACD
- SJT 0.04
- LXEO -0.17
- Stochastic Oscillator
- SJT 60.00
- LXEO 3.47
About SJT San Juan Basin Royalty Trust
San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.